Drug intelligence / Profile preview

HM242-Gel

Development stage: Unknown
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

HM242-Gel is a topical gel formulation under clinical investigation for its efficacy in *wound healing*. The primary objective of clinical trials has been to demonstrate that HM242-Gel performs at least comparably to INTRASITE Gel, a standard wound care product, with regard to wound healing. Specific details about its active ingredient(s), mechanism of action, or formulation have not been disclosed in available clinical records. The manufacturer, developer, and specific modality are not identified in public sources. The drug is being investigated as a wound treatment, most directly as a hydrogel-like topical medication for cutaneous ulcers and wounds[7].

Brand names: HM242-GelHM-242-GelHM 242-Gel
Other names: HM242-GelHM-242-GelHM 242-Gel

Beyond the preview

Go deeper on HM242-Gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HM242-Gel.

Explore the full profile